Zoetis Inc

ZTS's Fundamental analysis

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

ZTS Growth rates comparisons

Looking into Zoetis Inc growth rates, revenue grew by 0.5 % in the third quarter of 2025 from the same quarter a year ago. Ranking at No. 861

Major Pharmaceutical Preparations industry recorded growth of revenues by 10.29 %

Zoetis Inc 's net income grew by 4.19 % in third quarter of 2025 year on year, above company average,

• More on ZTS's Growth

ZTS's Valuation comparisons

Zoetis Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Zoetis Inc PEG ratio is at 2.1 Company is currently trading with Price to Cash flow multiple of 173.04 in trailing twelve-month period.

Company

24.32

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 6.81.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.86.

• More on ZTS's Valuation

Total Debt (Millions $)	7,069
Dividend TTM ($)	2 $
Dividend Yield TTM (%)	1.38 %
Revenue/Employee (TTM) $	666,454
Net Income/Employee (TTM) $	188,014
Receivable Turnover (TTM)	6.53
Tangible Book Value (Per Share $)	3.60

ZTS's Valuation comparisons

Company

24.32

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 6.81.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.86.

Zoetis Inc Price to Book Ratio is at 11.86 lower than Industry Avg. of 39.16. and higher than S&P 500 Avg. of 0.02

• More on ZTS's Valuation

• Market Capitalization (Millions $)	64,025
• Shares Outstanding (Millions)	443
• Employees	14,100
• Revenues (TTM) (Millions $)	9,397
• Net Income (TTM) (Millions $)	2,651
• Cash Flow (TTM) (Millions $)	370
• Capital Exp. (TTM) (Millions $)	-676
• Total Debt (Millions $)	7,069
• Dividend TTM ($)	2 $
• Dividend Yield TTM (%)	1.38 %
• Revenue/Employee (TTM) $	666,454
• Net Income/Employee(TTM) $	188,014
• Receivable Turnover Ratio (TTM)	6.53
• Tangible Book Value (Per Share $)	3.60

• Market Capitalization (Millions $)	64,025
• Shares Outstanding (Millions)	443
• Employees	14,100
• Revenues (TTM) (Millions $)	9,397
• Net Income (TTM) (Millions $)	2,651
• Cash Flow (TTM) (Millions $)	370
• Capital Exp. (TTM) (Millions $)	-676

ZTS's Profitability Comparisons

Zoetis Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in third quarter of 2025 to 38.83 % from 38.98 % in II. Quarter.

Zoetis Inc net profit margin of 30.04 % is currently ranking no. 15 in Major Pharmaceutical Preparations industry, ranking no. 23 in Healthcare sector and number 264 in S&P 500.

Profitability by Segment
International	68.63 %
Total	30.04 %

	*Ratio*
• Capital Ratio (MRQ)	3.64
• Total Debt to Equity (MRQ)	1.31
• Tangible Leverage Ratio (MRQ)	6.12
• Asset Turnover Ratio (TTM)	0.66
• Inventory Turnover Ratio (TTM)	1.11

ZTS's Profitability Comparisons

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.